Stenotrophomonas maltophilia – Clinical Significance, Treatment of Infections

1. Araoka H., Yoneyama A.: Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 14, 355–363 (2012) AraokaH. YoneyamaA. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy Transpl Infect Dis. 14 355 363 2012 Search in Google Scholar

2. Avison M.B., Higgins C.S., von Heldreich C.J., Walsh T.R.: Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 45, 413–419 (2001) AvisonM.B. HigginsC.S. von HeldreichC.J. WalshT.R. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia Antimicrob Agents Chemother. 45 413 419 2001 Search in Google Scholar

3. Aydemir C., Aktas E., Eldes N., Kutsal E., Demirel F., Ege A.: Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis. Turk J Pediatr. 50, 89–90 (2008) AydemirC. AktasE. EldesN. KutsalE. DemirelF. EgeA. Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis Turk J Pediatr. 50 89 90 2008 Search in Google Scholar

4. Bartoszek D., Fleischer M.: Znaczenie kliniczne Stenotrophomonas maltophilia. Forum zakażeń, 4, 165–171 (2013) BartoszekD. FleischerM. Znaczenie kliniczne Stenotrophomonas maltophilia Forum zakażeń 4 165 171 2013 Search in Google Scholar

5. Belzer A., Weiss E., Etaee F., Bunick C.G., Damsky W., Nelson C.A.: Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics, 11, DOII:10.3390/antibiotics11101398 (2022) BelzerA. WeissE. EtaeeF. BunickC.G. DamskyW. NelsonC.A. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature Antibiotics 11 10.3390/antibiotics11101398 2022 Open DOISearch in Google Scholar

6. Bin Abdulhak A.A., Zimmerman V., Al Beirouti B.T., Baddour L.M., Tleyjeh I.M.: Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn Microbiol Infect Dis. 63, 330–333 (2009) Bin AbdulhakA.A. ZimmermanV. Al BeiroutiB.T. BaddourL.M. TleyjehI.M. Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature Diagn Microbiol Infect Dis. 63 330 333 2009 Search in Google Scholar

7. Bostanghadiri N., Ghalavand Z., Fallah F., Yadegar A., Ardebili A., Tarashi S., Pournajaf A., Mardaneh J., Shams S., Hashemi A.: Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran. Front Microbiol. 10, DOI:10.3389/fmicb.2019.01191 (2019) BostanghadiriN. GhalavandZ. FallahF. YadegarA. ArdebiliA. TarashiS. PournajafA. MardanehJ. ShamsS. HashemiA. Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran Front Microbiol. 10 10.3389/fmicb.2019.01191 2019 Open DOISearch in Google Scholar

8. Brooke J.S.: Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 34, DOI:10.1128/CMR.00030-19 (2021) BrookeJ.S. Advances in the microbiology of Stenotrophomonas maltophilia Clin Microbiol Rev. 34 10.1128/CMR.00030-19 2021 Open DOISearch in Google Scholar

9. Brooke J.S.: Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol Rev. 25, 2–41 (2012) BrookeJ.S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen Clin. Microbiol Rev. 25 2 41 2012 Search in Google Scholar

10. Chang Y.T., Lin C.Y., Chen Y.H., Hsueh P.R.: Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 6, DOI:10.3389/fmicb.2015.00893 (2015) ChangY.T. LinC.Y. ChenY.H. HsuehP.R. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options Front Microbiol. 6 10.3389/fmicb.2015.00893 2015 Open DOISearch in Google Scholar

11. Chen S., Zou D.: Prognosis of hospital-acquired pneumonia/ventilator-associated pneumonia with Stenotrophomonas maltophiliaversus, Klebsiella pneumoniae in intensive care unit: A retrospectivecohort study. Clin Respir J. 16, 669–676 (2022) ChenS. ZouD. Prognosis of hospital-acquired pneumonia/ventilator-associated pneumonia with Stenotrophomonas maltophiliaversus, Klebsiella pneumoniae in intensive care unit: A retrospectivecohort study Clin Respir J. 16 669 676 2022 Search in Google Scholar

12. Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 31 ed. Wayne, PA, 2021, https://clsi.org/media/z2uhcbmv/m100ed31_sample.pdf (14.03.2023) Clinical and Laboratory Standards Institute M100: Performance Standards for Antimicrobial Susceptibility Testing 31 ed. Wayne, PA 2021 https://clsi.org/media/z2uhcbmv/m100ed31_sample.pdf (14.03.2023) Search in Google Scholar

13. Cowart MC, Ferguson CL.: Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Ther Drug Monit. 43, 146–149 (2021) CowartMC FergusonCL. Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study Ther Drug Monit. 43 146 149 2021 Search in Google Scholar

14. Duan Z., Qin J., Liu Y., Li C., Ying C.: Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital. BMC Microbiol. 20, DOI:10.1186/s12866-020-01985-3 (2020) DuanZ. QinJ. LiuY. LiC. YingC. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital BMC Microbiol. 20 10.1186/s12866-020-01985-3 2020 Open DOISearch in Google Scholar

15. Dzierżanowska D.: Antybiotykoterapia praktyczna. α-medica press, Bielsko-Biała, 2018 DzierżanowskaD. Antybiotykoterapia praktyczna α-medica press Bielsko-Biała 2018 Search in Google Scholar

16. Farrell D.J., Sader H.S., Jones R.N.: Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 54, 2735–2737 (2010) FarrellD.J. SaderH.S. JonesR.N. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections Antimicrob Agents Chemother. 54 2735 2737 2010 Search in Google Scholar

17. Fluit, A.C., Bayjanov, J.R., Aguilar, M.D., Cantón R., Elborn S., Tunney M.M., Scharringa J., Benaissa-Trouw B.J., Ekkelenkamp M.B.: Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections. BMC Microbiol. 22, DOI:10.1186/s12866-022-02466-5 (2022) FluitA.C. BayjanovJ.R. AguilarM.D. CantónR. ElbornS. TunneyM.M. ScharringaJ. Benaissa-TrouwB.J. EkkelenkampM.B. Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections BMC Microbiol. 22 10.1186/s12866-022-02466-5 2022 Open DOISearch in Google Scholar

18. Forrester J.B., Steed L.L, Santevecchi B.A., Flume P., Palmer-Long G.E., Bosso J.A.: In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infect Dis. 5, DOI:10.1093/ofid/ofy158 (2018) ForresterJ.B. SteedL.L SantevecchiB.A. FlumeP. Palmer-LongG.E. BossoJ.A. In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates Open Forum Infect Dis. 5 10.1093/ofid/ofy158 2018 Open DOISearch in Google Scholar

19. Gajdács M., Urbán E.: A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. Eur J Microbiol Immunol (Bp). 10, 91–97 (2020) GajdácsM. UrbánE. A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary Eur J Microbiol Immunol (Bp) 10 91 97 2020 Search in Google Scholar

20. Gajdacs M., Urban E.: Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory track: a 10-year epidemiological snapshot. Health Serv Res Manag Epidemiol. 15, DOI:0.1177/2333392819870774 (2019) GajdacsM. UrbanE. Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory track: a 10-year epidemiological snapshot Health Serv Res Manag Epidemiol. 15 10.1177/2333392819870774 2019 Open DOISearch in Google Scholar

21. Gallagher T., Phan J., Oliver A., Chase A.B., England W.E., Wandro S., Hendrickson C., Riedel S.F., Whiteson K.: Cystic fibrosis-associates Stenotrophomonas maltophilia strain specific adaptations and responses to pH. J Bacteriol. 13, DOI:10.1128/JB.00478-18 (2019) GallagherT. PhanJ. OliverA. ChaseA.B. EnglandW.E. WandroS. HendricksonC. RiedelS.F. WhitesonK. Cystic fibrosis-associates Stenotrophomonas maltophilia strain specific adaptations and responses to pH J Bacteriol. 13 10.1128/JB.00478-18 2019 Open DOISearch in Google Scholar

22. Geller M., Nunes C.P., Oliviera L., Nigri R.: S. maltophilia pneumonia: a case report. Respir Med Case Rep. 24, 44–45 (2018) GellerM. NunesC.P. OlivieraL. NigriR. S. maltophilia pneumonia: a case report Respir Med Case Rep. 24 44 45 2018 Search in Google Scholar

23. Gibb J.; Wong D.W.: Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies. Antibiotics, 10, DOI:10.3390/antibiotics10101226 (2021) GibbJ. WongD.W. Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies Antibiotics 10 10.3390/antibiotics10101226 2021 Open DOISearch in Google Scholar

24. Gordon N.C., Wareham D.W.: Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 65, 483–489 (2010) GordonN.C. WarehamD.W. Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia J Antimicrob Chemother. 65 483 489 2010 Search in Google Scholar

25. Granchelli A.M., Adler F.R., Keogh R.H., Kartsonaki C., Cox D.R., Liou T.G.: Microbial Interactions in the cystic fibrosis airway. J Clin Microbiol. 56, DOI: 10.1128/JCM.00354-18 (2018) GranchelliA.M. AdlerF.R. KeoghR.H. KartsonakiC. CoxD.R. LiouT.G. Microbial Interactions in the cystic fibrosis airway J Clin Microbiol. 56 10.1128/JCM.00354-18 2018 Open DOISearch in Google Scholar

26. Grillon A., Schramm F., Kleinberg M., Jehl F.: Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. PLoS One, 11, DOI:10.1371/journal.pone.0156690 (2016) GrillonA. SchrammF. KleinbergM. JehlF. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies PLoS One 11 10.1371/journal.pone.0156690 2016 Open DOISearch in Google Scholar

27. Guerci P., Bougle A. i wsp. AZUREA research network.: Outcomes of Stenotrophomonas maltophilia hospital-aquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 23. DOI: 10.1186/s13054-019-2649-5 (2019) GuerciP. BougleA. AZUREA research network Outcomes of Stenotrophomonas maltophilia hospital-aquired pneumonia in intensive care unit: a nationwide retrospective study Crit Care. 23 10.1186/s13054-019-2649-5 2019 Open DOISearch in Google Scholar

28. Healthcare-associated infections in intensive care units – Annual Epidemiological Report for 2017. European Centre for Disease Prevention and Control, 2019, https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1 (14.03.2023) Healthcare-associated infections in intensive care units – Annual Epidemiological Report for 2017 European Centre for Disease Prevention and Control 2019 https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1 (14.03.2023) Search in Google Scholar

29. Huan Y., Kong Q., Mou H., Yi H.: Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front. Microbiol. 11, DOI:10.3389/fmicb.2020.582779 (2020) HuanY. KongQ. MouH. YiH. Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields Front. Microbiol. 11 10.3389/fmicb.2020.582779 2020 Open DOISearch in Google Scholar

30. Huertas Méndez N.J., Vargas Casanova Y., Gómez Chimbi A.K., Hernández E., Leal Castro A.L., Melo Diaz J.M., Rivera Monroy Z.J., García Castañeda J.E.: Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076. Molecules, 22, DOI:10.3390/molecules22030452 (2017) Huertas MéndezN.J. Vargas CasanovaY. Gómez ChimbiA.K. HernándezE. Leal CastroA.L. Melo DiazJ.M. Rivera MonroyZ.J. García CastañedaJ.E. Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076 Molecules 22 10.3390/molecules22030452 2017 Open DOISearch in Google Scholar

31. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0,3/31/2022 https://www.idsociety.org/news-publications-new/articles/2021/new-guidance-for-treating-antimicrobial-resistantinfections-released/ (14.03.2023) IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0,3/31/2022 https://www.idsociety.org/news-publications-new/articles/2021/new-guidance-for-treating-antimicrobial-resistantinfections-released/ (14.03.2023) Search in Google Scholar

32. Imoto W., Kakeya H. i wsp.: Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern Med. 59, 193–198 (2020) ImotoW. KakeyaH. Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia Intern Med. 59 193 198 2020 Search in Google Scholar

33. Insuwanno W., Kiratisin P., Jitmuang A.: Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients. Infect. Drug. Resist. 13, 1559–1566 (2020) InsuwannoW. KiratisinP. JitmuangA. Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients Infect. Drug. Resist. 13 1559 1566 2020 Search in Google Scholar

34. Jacobson S., Junco Noa L., Wallace M.R., Bowman M.C.: Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 71, 3620–3622 (2016) JacobsonS. Junco NoaL. WallaceM.R. BowmanM.C. Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections J Antimicrob Chemother. 71 3620 3622 2016 Search in Google Scholar

35. Jiang Z., Ren Y., Zhang C., Yin Y., Li C.: Community-Acquired Stenotrophomonas Maltophilia Infection in a Child: A Case Report and Literature Review. Infect Drug Resist. 15, 5469–5474 (2022) JiangZ. RenY. ZhangC. YinY. LiC. Community-Acquired Stenotrophomonas Maltophilia Infection in a Child: A Case Report and Literature Review Infect Drug Resist. 15 5469 5474 2022 Search in Google Scholar

36. Kalidasan V., Joseph N., Kumar S., Awang Hamat R., Neela V.K.: Iron and Virulence in Stenotrophomonas Maltophilia: All We Know So Far. Front. Cell. Infect. Microbiol. DOI:10.3389/fcimb.2018.00401 (2018) KalidasanV. JosephN. KumarS. Awang HamatR. NeelaV.K. Iron and Virulence in Stenotrophomonas Maltophilia: All We Know So Far Front. Cell. Infect. Microbiol. 10.3389/fcimb.2018.00401 2018 Open DOISearch in Google Scholar

37. Kanchanasuwan S., Rongmuang J., Siripaitoon P.; Kositpantawong N., Charoenmak B., Hortiwakul T., Nwabor O.F., Chusri S.: Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia. J. Clin. Med. 11, DOI:10.3390/jcm11113085 (2022) KanchanasuwanS. RongmuangJ. SiripaitoonP. KositpantawongN. CharoenmakB. HortiwakulT. NwaborO.F. ChusriS. Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia J. Clin. Med. 11 10.3390/jcm11113085 2022 Open DOISearch in Google Scholar

38. Khan A., Pettaway C., Dien B.J., Arias C.A., Bhatti M.M., Humphries R.M.: Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 65, DOI:10.1128/AAC.02631-20 (2021) KhanA. PettawayC. DienB.J. AriasC.A. BhattiM.M. HumphriesR.M. Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia Antimicrob Agents Chemother. 65 10.1128/AAC.02631-20 2021 Open DOISearch in Google Scholar

39. Kim E.J., Kim Y.C., Ahn J.Y., Jeong S.J., Ku N.S., Choi J.Y., Yeom J., Song Y.G.: Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteriemia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 19, DOI:10.1186/s12879-019-4394-4 (2019) KimE.J. KimY.C. AhnJ.Y. JeongS.J. KuN.S. ChoiJ.Y. YeomJ. SongY.G. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteriemia and clinical impact of quinolone-resistant strains BMC Infect Dis. 19 10.1186/s12879-019-4394-4 2019 Open DOISearch in Google Scholar

40. Mahdi O., Eklund B., Fisher N.: Laboratory culture and maintenance of Stenotrophomonas maltophilia. Curr. Protoc. Microbiol. DOI:10.1002/9780471729259.mc06f01s32 (2014) MahdiO. EklundB. FisherN. Laboratory culture and maintenance of Stenotrophomonas maltophilia Curr. Protoc. Microbiol. 10.1002/9780471729259.mc06f01s32 2014 Open DOISearch in Google Scholar

41. Martinez-Servat S., Yero D., Huedo P., Marquez R., Molina G., Daura X., Gibert I.: Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing. Front. Microbiol. 9, DOI:10.3389/fmicb.2018.02871 (2018) Martinez-ServatS. YeroD. HuedoP. MarquezR. MolinaG. DauraX. GibertI. Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing Front. Microbiol. 9 10.3389/fmicb.2018.02871 2018 Open DOISearch in Google Scholar

42. Menetrey Q., Sorlin P., Jumas-Bilak E., Chiron R., Dupont C., Marchandin H. Achromobacter xylosoxidans and Stenotrophomonas maltophilia: emerging pathogens well-armed for life in the cystic fibrosis patients’ lung. Genes, 12, DOI:10.3390/genes12050610 (2021) MenetreyQ. SorlinP. Jumas-BilakE. ChironR. DupontC. MarchandinH. Achromobacter xylosoxidans and Stenotrophomonas maltophilia: emerging pathogens well-armed for life in the cystic fibrosis patients’ lung Genes 12 10.3390/genes12050610 2021 Open DOISearch in Google Scholar

43. Mojica M.F., Humphries R., Lipuma J.J., Mathers A.J., Rao G.G., Shelburne S.A., Fouts D.E., Van Duin D., Bonomo R.A.: Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob. Resist. DOI:10.1093/jacamr/dlac040 (2022) MojicaM.F. HumphriesR. LipumaJ.J. MathersA.J. RaoG.G. ShelburneS.A. FoutsD.E. Van DuinD. BonomoR.A. Clinical challenges treating Stenotrophomonas maltophilia infections: an update JAC Antimicrob. Resist. 10.1093/jacamr/dlac040 2022 Open DOISearch in Google Scholar

44. Mojica M.F., Rutter J.D., Taracila M., Abriata L.A., Fouts D.E., Papp-Wallace K.M., Walsh T.J., LiPuma J.J., Vila A.J., Bonomo R.A.: Population Structure, Molecular Epidemiology, and beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio, 10, DOI:10.1128/mBio.00405-19 (2019) MojicaM.F. RutterJ.D. TaracilaM. AbriataL.A. FoutsD.E. Papp-WallaceK.M. WalshT.J. LiPumaJ.J. VilaA.J. BonomoR.A. Population Structure, Molecular Epidemiology, and beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States mBio 10 10.1128/mBio.00405-19 2019 Open DOISearch in Google Scholar

45. Moriceau C., Eveillard M., Lemarié C., Chenouard R., Pailhoriès H., Kempf M.: Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone. Méd. Mal. Infect. 50, 305–307 (2020) MoriceauC. EveillardM. LemariéC. ChenouardR. PailhorièsH. KempfM. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone Méd. Mal. Infect. 50 305 307 2020 Search in Google Scholar

46. Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C.: In Vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI:10.1128/AAC.01699-19 (2020) MorrisseyI. OleskyM. HawserS. LobS.H. KarlowskyJ.A. CoreyG.R. BassettiM. FyfeC. In Vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 Antimicrob. Agents Chemother. 64 10.1128/AAC.01699-19 2020 Open DOISearch in Google Scholar

47. Okazaki A., Avison M.B.: Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 51, 359–360 (2007) OkazakiA. AvisonM.B. Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia Antimicrob Agents Chemother. 51 359 360 2007 Search in Google Scholar

48. Osawa K., Shigemura K., Kitagawa K., Tokimatsu I., Fujisawa M.: Risk factors for death from Stenotrophomonas maltophilia bacteriemia. J Infect Chemother. 24, 632–636 (2018) OsawaK. ShigemuraK. KitagawaK. TokimatsuI. FujisawaM. Risk factors for death from Stenotrophomonas maltophilia bacteriemia J Infect Chemother. 24 632 636 2018 Search in Google Scholar

49. Pompilio A., Di Bonaventura G. i wsp.: Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed – helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. BMC Microbiol. 12, DOI:10.1186/1471-2180-12-145 (2012) PompilioA. Di BonaventuraG. Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed – helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia BMC Microbiol. 12 10.1186/1471-2180-12-145 2012 Open DOISearch in Google Scholar

50. Rello J., Kalwaje E.V., Lagunes L., Alves J., Wunderink R.G., Conway-Morris A., Rojas J.N., Alp E., Zhang Z.: A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 38, 319–323 (2019) RelloJ. KalwajeE.V. LagunesL. AlvesJ. WunderinkR.G. Conway-MorrisA. RojasJ.N. AlpE. ZhangZ. A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis Eur J Clin Microbiol Infect Dis. 38 319 323 2019 Search in Google Scholar

51. Said M.S., Tirthani E., Lesho E.: Stenotrophomonas maltophilia. StatPearls, Treasure Island, Floryda, StatPearls, 2022 SaidM.S. TirthaniE. LeshoE. Stenotrophomonas maltophilia. StatPearls, Treasure Island, Floryda StatPearls 2022 Search in Google Scholar

52. Simner P.J., Patel R.: Cefiderocol antimicrobial susceptibility testing considerations: The Achilles’ Heel of the Trojan Horse? J. Clin. Microbiol. 59, DOI:10.1128/JCM.00951-20 (2020) SimnerP.J. PatelR. Cefiderocol antimicrobial susceptibility testing considerations: The Achilles’ Heel of the Trojan Horse? J. Clin. Microbiol. 59 10.1128/JCM.00951-20 2020 Open DOISearch in Google Scholar

53. Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST, wersja 5.0, 15 grudnia 2021 https://korld.nil.gov.pl/wp-content/uploads/2022/03/Stanowisko-Zespolu-Roboczego-wersja-5_0-2021.pdf (14.03.2023) Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST, wersja 5.0 15 grudnia 2021 https://korld.nil.gov.pl/wp-content/uploads/2022/03/Stanowisko-Zespolu-Roboczego-wersja-5_0-2021.pdf (14.03.2023) Search in Google Scholar

54. Szewczyk M.E.: Diagnostyka bakteriologiczna. Wydawnictwo Naukowe PWN SA, Warszawa, 2019 SzewczykM.E. Diagnostyka bakteriologiczna Wydawnictwo Naukowe PWN SA Warszawa 2019 Search in Google Scholar

55. The European Committee on Antimicrobial Susceptibility Testing – EUCAST, Guidance document on broth microdilution testing of cefiderocol, December 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf (14.03.2023) The European Committee on Antimicrobial Susceptibility Testing – EUCAST Guidance document on broth microdilution testing of cefiderocol December 2020 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf (14.03.2023) Search in Google Scholar

56. The European Committee on Antimicrobial Susceptibility Testing „Clinical breakpoints – breakpoints and guidance”, January 1, 2022, https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (14.03.2023) The European Committee on Antimicrobial Susceptibility Testing „Clinical breakpoints – breakpoints and guidance” January 1 2022 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (14.03.2023) Search in Google Scholar

57. Trifonova A., Strateva T.: Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors, Infectious Diseases, 51, 168–178 (2019) TrifonovaA. StratevaT. Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors Infectious Diseases 51 168 178 2019 Search in Google Scholar

58. Trignano E., Manzo M.J., Fallico N., Maffei M., Marongiu F., Campus G.V., Rubino C.: First report of digital skin ulcer with Stenotrophomonas maltophilia infection in an immunocompetent patients. In Vivo, 28, 259–261 (2014) TrignanoE. ManzoM.J. FallicoN. MaffeiM. MarongiuF. CampusG.V. RubinoC. First report of digital skin ulcer with Stenotrophomonas maltophilia infection in an immunocompetent patients In Vivo 28 259 261 2014 Search in Google Scholar

59. Umar Z., Ashfaq S., Parikh A., Ilyas U., Foster A., Bhangal R., Khan J., Nassar M.: Stenotrophomonas maltophilia and urinary tract infections: a systematic review. Cureus. 14, DOI: 10.7759/cureus.26184 (2022) UmarZ. AshfaqS. ParikhA. IlyasU. FosterA. BhangalR. KhanJ. NassarM. Stenotrophomonas maltophilia and urinary tract infections: a systematic review Cureus. 14 10.7759/cureus.26184 2022 Open DOISearch in Google Scholar

60. Walkty A., Adam H., Baxter M., Denisuik A., Lagacé-Wiens P., Karlowsky J.A., Hoban D.J., Zhanel G.G.: In Vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob. Agents Chemother. 58, 2554–2563 (2014) WalktyA. AdamH. BaxterM. DenisuikA. Lagacé-WiensP. KarlowskyJ.A. HobanD.J. ZhanelG.G. In Vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012 Antimicrob. Agents Chemother. 58 2554 2563 2014 Search in Google Scholar

61. Wang N., Tang C., Wang L.: Risk Factors for Acquired Stenotrophomonas maltophilia Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis. Front. Med. 8, DOI:10.3389/fmed.2021.808391 (2022) WangN. TangC. WangL. Risk Factors for Acquired Stenotrophomonas maltophilia Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis Front. Med. 8 10.3389/fmed.2021.808391 2022 Open DOISearch in Google Scholar

62. Wang Y.L., Scipione M.R., Dubrovskaya Y., Papadopoulos J.: Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 58, 176–182 (2014) WangY.L. ScipioneM.R. DubrovskayaY. PapadopoulosJ. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections Antimicrob Agents Chemother. 58 176 182 2014 Search in Google Scholar

63. Zając O., Laudy A.E., Tyski S.: Biofilm, pompy MDR i inne mechanizmy oporności Stenotrophomonas maltophilia na związki przeciwdrobnoustrojowe. Post. Mikrobiol. 53, 264–276 (2014) ZającO. LaudyA.E. TyskiS. Biofilm, pompy MDR i inne mechanizmy oporności Stenotrophomonas maltophilia na związki przeciwdrobnoustrojowe Post. Mikrobiol. 53 264 276 2014 Search in Google Scholar

64. Zajac O.M., Tyski S., Laudy A.E.: Phenotypic and Molecular Characteristics of the MDR Efflux Pump Gene-Carrying Stenotrophomonas maltophilia Strains Isolated in Warsaw, Poland. Biology, 11, DOI:10.3390/biology11010105 (2022) ZajacO.M. TyskiS. LaudyA.E. Phenotypic and Molecular Characteristics of the MDR Efflux Pump Gene-Carrying Stenotrophomonas maltophilia Strains Isolated in Warsaw, Poland Biology 11 10.3390/biology11010105 2022 Open DOISearch in Google Scholar

65. Zhanel G.G., Karlowsky J.A. i wsp.: Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-_-lactamase inhibitor combinations. Drugs, 78, 65–98 (2018) ZhanelG.G. KarlowskyJ.A. Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-_-lactamase inhibitor combinations Drugs 78 65 98 2018 Search in Google Scholar

66. Zhu L., Ye X. i wsp.: Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteriemia: a retrospective study. BMC Infect Dis. 21, DOI:10.1186/s12879-021-06420-0 (2021) ZhuL. YeX. Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteriemia: a retrospective study BMC Infect Dis. 21 10.1186/s12879-021-06420-0 2021 Open DOISearch in Google Scholar

67. Zöllner S.K., Kampmeier S., Froböse N.J., Herbrüggen H., Masjosthusmann K., van den Heuvel A., Reicherts C., Ranft A., Groll A.H.: Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology. Front Oncol. 11, DOI:10.3389/fonc.2021.752037 (2021) ZöllnerS.K. KampmeierS. FroböseN.J. HerbrüggenH. MasjosthusmannK. van den HeuvelA. ReichertsC. RanftA. GrollA.H. Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology Front Oncol. 11 10.3389/fonc.2021.752037 2021 Open DOISearch in Google Scholar